M
Mitsumasa Kishimoto
Researcher at Kyorin University
Publications - 131
Citations - 2361
Mitsumasa Kishimoto is an academic researcher from Kyorin University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 18, co-authored 91 publications receiving 1454 citations. Previous affiliations of Mitsumasa Kishimoto include International University, Cambodia.
Papers
More filters
Journal ArticleDOI
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
Désirée van der Heijde,Atul Deodhar,Walter P. Maksymowych,Joachim Sieper,Filip Van den Bosch,Tae-Hwan Kim,Mitsumasa Kishimoto,Andrew J. K. Östör,Bernard Combe,Yunxia Sui,YuanYuan Duan,Peter K. Wung,In-Ho Song +12 more
TL;DR: Upadacitinib 15 mg once daily showed sustained and consistent efficacy over 2 years for ASAS40 and other clinically relevant endpoints and a low rate of radiographic progression was observed and no new safety findings were observed.
Journal ArticleDOI
Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study
D. Benavent,Ch. Plasencia,Denis Poddubnyy,Mitsumasa Kishimoto,Fabian Proft,H. Sawada,Clementina López-Medina,Maxime Dougados,Victoria Navarro-Compán +8 more
TL;DR: The ASAS-perSpa study as mentioned in this paper showed that axial involvement in patients with PsA was significantly associated with male gender (OR=1.68), elevated CRP (OR = 2.87), and absence of psoriasis (OR ≥ 0.33).
Proceedings ArticleDOI
Op0234 efficacy and safety of brodalumab, an anti-interleukin-17 receptor a monoclonal antibody, in patients with axial spondyloarthritis: a 16 week results of a phase 3, multicenter, randomized, double-blind, placebo-controlled study
James Cheng-Chung Wei,Tae-Hwan Kim,Mitsumasa Kishimoto,Takuya Morishige,Naoki Ogusu,Shigeto Kobayashi +5 more
TL;DR: Bdalumab s.c. 210 mg Q2W treatment was effective and tolerable in axSpA patients in this 16 week phase 3 clinical trial and could be considered as a future therapeutic option for patients with ax spondyloarthritis.
Journal ArticleDOI
Does exercise therapy improve patient-reported outcomes in rheumatoid arthritis? A systematic review and meta-analysis for the update of the 2020 JCR guidelines for the management of rheumatoid arthritis.
Yasumori Sobue,Toshihisa Kojima,Hiromu Ito,Keiichiro Nishida,Isao Matsushita,Yuko Kaneko,Mitsumasa Kishimoto,Masataka Kohno,Takahiko Sugihara,Yohei Seto,Eiichi Tanaka,Takeo Nakayama,Shintaro Hirata,Atsuko Murashima,Akio Morinobu,Masaaki Mori,Masayo Kojima,Yutaka Kawahito,Masayoshi Harigai +18 more
TL;DR: In this paper, the authors evaluated the impact of exercise therapy on patient-reported outcomes (PROs) in rheumatoid arthritis (RA) as part of the process of updating the 2020 Japanese guidelines for the...
Journal ArticleDOI
Use of Hydroxychloroquine in Japan
TL;DR: To the Editor: Antimalarial agents have been used for the treatment of inflammatory diseases for the last half century, with hydroxychloroquine (HCQ) being approved in the United States in 1955.